Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome

J Pharm Pharmacol. 2009 Nov;61(11):1505-10. doi: 10.1211/jpp/61.11.0010.


Objectives: Inflammation and platelet aggregation and activation are key processes in the initiation of a cardiovascular event. Patients with metabolic syndrome have a high risk of cardiovascular events. This study determined whether small and medium doses of aspirin have anti-inflammation and antiplatelet aggregation effects in patients with metabolic syndrome.

Methods: One hundred and twenty-one consecutive patients with metabolic syndrome were randomized into three groups, receiving 100 mg/day of aspirin, 300 mg/day of aspirin or a placebo, respectively, for 2 weeks. The blood levels of thromboxane B2 (TXB2), a stable product of the platelet aggregation mediator TXA2, 6-keto-prostaglandin F1-alpha (6-keto-PGF1-alpha), a stable product of the endogenous cyclooxygenase metabolite prostaglandin I2, and inflammatory mediators including high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), were determined by ELISA and radioimmunoassay.

Key findings: The blood levels of hs-CRP, TNF-alpha, IL-6 and TXB2 were significantly decreased after 2 weeks of treatment with 300 mg/day of aspirin. Patients who received 100 mg/day of aspirin had decreased blood levels of hs-CRP and TXB2. The blood level of IL-6 in the 300 mg/day aspirin group was significantly lower than that in the other two groups after 2 weeks of therapy. Aspirin at either dose did not affect the blood level of 6-keto-PGF1-alpha.

Conclusions: Aspirin at all doses suppresses the blood levels of inflammatory markers and the platelet aggregation mediator TXA2 in Chinese patients with metabolic syndrome. Since the suppression induced by 300 mg/day of aspirin was greater than that induced by 100 mg/day of aspirin, these data suggest that 300 mg/day of aspirin may be beneficial in decreasing the risk of cardiovascular events in Chinese patients with metabolic syndrome.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / pharmacology
  • Aspirin / administration & dosage*
  • Aspirin / pharmacology
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Cardiovascular Diseases / prevention & control*
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation / drug therapy*
  • Inflammation Mediators / blood*
  • Interleukin-6 / blood
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / drug therapy*
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / pharmacology
  • Prospective Studies
  • Thromboxane B2 / blood
  • Tumor Necrosis Factor-alpha / blood


  • Anti-Inflammatory Agents
  • Biomarkers
  • Inflammation Mediators
  • Interleukin-6
  • Platelet Aggregation Inhibitors
  • Tumor Necrosis Factor-alpha
  • Thromboxane B2
  • C-Reactive Protein
  • Aspirin